Tumor Board Tuesday 2024: Gastrointestinal Cancers

PROVIDER STATEMENT

Provided by Integrity CE, LLC and Tumor Board Tuesday.

DISCLOSURE OF COMMMERCIAL SUPPORT

Supported by educational grants from Astellas Pharma Global, AstraZeneca, Janssen Scientific Affairs, LLC, Lilly, Novartis, Seagen and Taiho Oncology.

MODERATORS

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time.

DateTopicFacultyDisclosuresConversations
Tuesday, October 1, 2024
Advanced HCC Treatment in the IO Era
AMA credit
Ghassan Abou-Alfa, MD
Attending Physician
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical School at Cornell University
New York, NY

Layla Mahmasani, MD
Oncology Fellow
Memorial Sloan Kettering Cancer Center
New York, NY
Ghassan Abou-Alfa, MD
Consulting: Abbvie, Alligator, Astra Zeneca, Autem, Berry Genomics, BioNtech, Boehringer Ingelheim, BMS, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva
Research: Agenus, Arcus, Astra Zeneca, BioNtech, BMS, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva

Layla Mahmasani, MD has no real or apparent conflicts to disclose
Tuesday, September 3, 2024Claudin 18.2 in Gastric Cancer
AMA credit
Sunnie Kim, MD
Associate Professor
GI Medical Oncologist
University of Colorado Comprehensive Cancer Center

Nicole Baranda Balmaceda, MD
Hematology/Oncology Fellow Physician
University of Colorado Anschutz Medical Campus
Sunnie Kim, MD
Advisory Board: Bristol Myers Squibb, Daiichi Sankyo, Eisai, IMAB, Merck
Consultant: Amgen

Nicole Baranda Balmaceda, MD has no real or apparent conflicts to disclose
Tuesday, July 9, 2024Durva + TACE for HCC
AMA credit
Mark Yarchoan, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, MD

Ellery Altshuler, MD
Hematology-Oncology Fellow
Mark Yarchoan, MD
Grant or research support: Genentech, Inc.
Consultant: Adventris Pharmaceuticals, Genentech, Inc.
Grant or research support: Adventris Pharmaceuticals, Bristol-Myers Squibb

Ellery Altshuler, MD has no real or apparent conflicts to disclose.
Tuesday, April 23, 2024SDHB mutation in a metastatic paraganglioma
AMA credit
Rachel Riechelmann, MD, PhD
Director, Clinical Oncology Department
Head, Neuroendocrine Tumors and Colorectal Cancer Research Center
AC Camargo Cancer Center
São Paulo, Brazil

Álvaro Oliveira, MD
Attending Physician
GI and Thoracic Clinical Oncology
AC Camargo Cancer Center
São Paulo, Brazil
Rachel Riechelmann, MD, PhD has no real or apparent conflicts to disclose.

Álvaro Oliveira, MD has no real or apparent conflicts to disclose.
Tuesday, March 26, 2024Targeting KRAS in Pancreatic Cancer
AMA credit
Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin
Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

Stay tuned for upcoming conversations!

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesday is a regularly scheduled, Twitter-based case discussion forum led by expert faculty modeled on the traditional tumor board presentation. Cases are based on realistic scenarios and supporting data is including for optimal treatment selection and patient management.

TARGET AUDIENCE

This activity is designed to meet the needs of medical, surgical and radiation oncologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with gastrointestinal cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from February 27, 2024 – March 19, 2025, you can do so here:  www.integrityce.com/TBTeval24

MEDIA

Internet

ACCREDITATION STATEMENT

Physician Continuing Education

Integrity CE, LLC  is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

The Integrity CE, LLC planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.